Inhaled corticosteroids administration/withdrawal as a therapeutic continuum for patients with chronic obstructive pulmonary disease in real clinical practice

Author:

Avdeev S. N.1ORCID,Aisanov Z. R.2ORCID,Arkhipov V. V.3ORCID,Belevskiy A. S.2ORCID,Vizel A. A.4ORCID,Demko I. V.5ORCID,Emelyanov A. V.6ORCID,Zaycev A. A.7ORCID,Ignatova G. L.8ORCID,Kniajeskaia N. P.2ORCID,Kudelya L. M.9ORCID,Leshchenko I. V.10ORCID,Ovcharenko S. I.11ORCID,Sinopalnikov A. I.3ORCID,Trofimenko I. N.12ORCID,Fedotov V. D.13ORCID,Khamitov R. F.4ORCID

Affiliation:

1. Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University); Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia

2. Pirogov Russian National Research Medical University (Pirogov Medical University), Healthcare Ministry of Russia

3. Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia

4. Kazan’ State Medical University, Healthcare Ministry of Russia

5. Federal State Budgetary Educational Institution of Higher Education Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky, Ministry of Health of the Russian Federation

6. North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of the Russian Federation

7. Main Military Clinical Hospital named after academician N.N. Burdenko, Ministry of Defense of the Russian Federation; Federal State Budgetary Educational Institution of Higher Education Moscow State University of Food Production, Ministry of Science and Higher Education

8. South Ural State Medical University, Healthcare Ministry of Russia

9. Novosibirsk State Medical University, Healthcare Ministry of Russia; State budgetary healthcare institution of the Novosibirsk region State Novosibirsk Regional Clinical Hospital

10. Ural Federal State Medical University, Healthcare Ministry of Russia; Ural Federal Research Institute of Phthisiology and Pulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia; Limited Liability Company Novaya bol’nitsa Clinical Association

11. Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)

12. Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education Russian Medical Academy of Continuing Professional Education, Healthcare Ministry of the Russian Federation

13. Federal Budgetary Scientific Institution Nizhny Novgorod Research Institute for Hygiene and Occupational Pathology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Abstract

Chronic obstructive pulmonary disease (COPD) is a progressing disease. Each exacerbation impairs the patient’s prognosis and increases burden for the healthcare system. The most common maintenance treatment options for COPD include long-acting bronchodilators – β2-agonists (LABA) and long-acting antimuscarinic agents (LAMA), and inhaled glucocorticosteroids (ICS), in fixed/opened double and triple combinations. Triple therapy in subjects with exacerbation history is the most effective way to prevent negative outcomes of the disease. It can reduce the frequency of exacerbations, slow down the disease progression, improve quality of life, and reduce mortality in the long run. On the other hand, the response to triple therapy may change over the time depending on airways inflammation level, infection activity, and exacerbation frequency. Current COPD guidelines propose different indications for therapy escalation and de-escalation (ICS addition/withdrawal) for more personalized and safe treatment. At the same time, many practical issues of this process are still unclear, e.g. how often treatment regimens should be reviewed and what escalation/de-escalation criteria should be prioritized. The authors strongly believe that COPD therapy should adapt a holistic treatment approach (continuum) with quick responses to any changes in the patient’s condition.The aim of our work was to create an algorithm for ICS administration/ withdrawal for COPD patients on long-acting dual bronchodilators maintenance therapy and to establish a therapeutic continuum that takes into account exacerbation history, symptoms severity, blood eosinophilia level, and concomitant asthma.Conclusion. This instrument can be a useful and convenient tool for long-term patient management when access to specialized medical care might be restricted. It takes into account the main current recommendations for COPD management and is easy to apply in real clinical practice.

Publisher

Scientific and Practical Reviewed Journal Pulmonology

Subject

Pulmonary and Respiratory Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3